Your browser doesn't support javascript.
loading
Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials.
Al-Sawaf, O; Robrecht, S; Bahlo, J; Fink, A M; Cramer, P; V Tresckow, J; Lange, E; Kiehl, M; Dreyling, M; Ritgen, M; Dürig, J; Tausch, E; Schneider, C; Stilgenbauer, S; Wendtner, C M; Fischer, K; Hallek, M; Eichhorst, B.
Affiliation
  • Al-Sawaf O; Department I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany. othman.al-sawaf@uk-koeln.de.
  • Robrecht S; Department I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany.
  • Bahlo J; Department I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany.
  • Fink AM; Department I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany.
  • Cramer P; Department I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany.
  • V Tresckow J; Department I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany.
  • Lange E; Department of Hematology and Oncology, Evangelisches Krankenhaus Hamm, Hamm, Germany.
  • Kiehl M; Department of Internal Medicine, Frankfurt (Oder) General Hospital, Frankfurt/Oder, Germany.
  • Dreyling M; Department of Medicine III, University Hospital Ludwig Maximilians University, Munich, Germany.
  • Ritgen M; Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Dürig J; Department of Hematology, University Hospital Essen, Essen, Germany.
  • Tausch E; Department of Internal Medicine III, Ulm University, Ulm, Germany.
  • Schneider C; Department of Internal Medicine III, Ulm University, Ulm, Germany.
  • Stilgenbauer S; Department of Internal Medicine III, Ulm University, Ulm, Germany.
  • Wendtner CM; Department of Internal Medicine I, Saarland University Medical Center, Homburg, Germany.
  • Fischer K; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, German CLL Study Group, Munich Clinic Schwabing, Munich, Germany.
  • Goede; Department I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany.
  • Hallek M; Department I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany.
  • Eichhorst B; Oncogeriatric Unit, Department of Geriatric Medicine, St. Marienhospital, Cologne, Germany.
Leukemia ; 35(1): 169-176, 2021 01.
Article in En | MEDLINE | ID: mdl-32203141
ABSTRACT
Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The aim of this analysis is to report the frequency, characteristics and outcomes of pts with RT enrolled in trials of the GCLLSG. A total of 2975 pts with advanced CLL were reviewed for incidence of RT. Clinical, laboratory, and genetic data were pooled. Time-to-event data, starting from time of CLL diagnosis, of first-line therapy or of RT diagnosis, were analyzed by Kaplan-Meier methodology. One hundred and three pts developed RT (3%) 95 pts diffuse large B-cell lymphoma (92%) and eight pts Hodgkin lymphoma (8%). Median observation time was 53 months (interquartile range 38.1-69.5). Median OS from initial CLL diagnosis for pts without RT was 167 months vs 71 months for pts with RT (HR 2.64, CI 2.09-3.33). Median OS after diagnosis of RT was 9 months. Forty-seven pts (46%) received CHOP-like regimens for RT treatment. Three pts subsequently underwent allogeneic and two pts autologous stem cell transplantation. Our findings show that within a large cohort of GCLLSG trial participants, 3% of the pts developed RT after receiving first-line chemo- or chemoimmunotherapy. This dataset confirms the ongoing poor prognosis and high mortality associated with RT.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Cell Transformation, Neoplastic / Lymphoma Type of study: Clinical_trials / Etiology_studies / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Leukemia Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Cell Transformation, Neoplastic / Lymphoma Type of study: Clinical_trials / Etiology_studies / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Leukemia Year: 2021 Document type: Article